Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 333 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Listening to Patient Narratives June 9, 2020 How to Cope With Panic Attacks During Cancer July 12, 2022 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 Load more HOT NEWS Physical Activity May Lessen the Effects of Chemobrain, Study Finds Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... EMA Recommends Extension of Indications for Crizotinib Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced...
